S&P Futures
6,017.50 +30.50 (+0.51%) Dow Futures
44,700.00 +305.00 (+0.69%) Nasdaq Futures
20,969.25 +119.50 (+0.57%) Russell 2000 Futures
2,438.30 +24.70 (+1.02%) Crude Oil
71.09 -0.15 (-0.21%) Gold
2,688.70 -23.50 (-0.87%)
Alterity Therapeutics Limited (PRNAF)
| Previous Close | 0.0000 |
| Open | 0.0036 |
| Bid | 0.0004 x 0 |
| Ask | 0.0024 x 0 |
| Day's Range | 0.0036 - 0.0036 |
| 52 Week Range | 0.0002 - 0.0068 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 18.884M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | Feb 03, 2025 - Feb 04, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAlterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the
- GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System. “The data presented highligh
